RLMD | Relmada Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.8000 - 2.9150
52 Week Range	1.8800 - 7.22
Beta	0.04
Implied Volatility	189.74%
IV Rank	93.49%
Day's Volume	105,005
Average Volume	182,371
Shares Outstanding	30,174,200
Market Cap	86,599,954
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-06-20

Valuation
Profitability
Growth
Health
P/E Ratio	-1.00
Forward P/E Ratio	N/A
EPS	-2.86
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	20
Country	USA
Website	RLMD

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

RLMD's peers: CYTK, DICE, EWTX, KRTX, DYN, THRD, PMVP, ENOB, RVMD, PRDS, STTK, ELYM, CSBR, IPSC, FUSN, BCYC, RAPT, NAMS, CYT, NUVB, MGTA, NLTX, GRPH

*Chart delayed

Analyzing fundamentals for RLMD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see RLMD Fundamentals page.

Watching at RLMD technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on RLMD Technicals page.